Cargando…

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate

Ferric pyrophosphate citrate (FPC) is indicated to maintain hemoglobin in patients with stage 5 hemodialysis‐dependent chronic kidney disease on chronic hemodialysis by addition to the dialysate. An intravenous (IV) FPC presentation containing 6.75 mg of iron in 4.5 mL was developed. The objective w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marbury, Thomas, van Heuveln, Fred, van der Horst, Eric, Pratt, Raymond D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Pharmacokinetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303319/ https://www.ncbi.nlm.nih.gov/pubmed/34743348 http://dx.doi.org/10.1002/jcph.1997

Ejemplares similares

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers
por: Pratt, Raymond D., et al.
Publicado: (2016)

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis
por: Pratt, Raymond D., et al.
Publicado: (2018)

Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis
por: Zhang, Lingxiao, et al.
Publicado: (2022)

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients
por: Fishbane, Steven N., et al.
Publicado: (2015)

Physicochemical characterization of ferric pyrophosphate citrate
por: Gupta, Ajay, et al.
Publicado: (2018)

Ferric pyrophosphate citrate: interactions with transferrin
por: Pratt, Raymond, et al.
Publicado: (2018)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Metabolism, Excretion, and Pharmacokinetics of [(14)C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
por: Miyazaki, Shiro, et al.
Publicado: (2019)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
por: Hoglund, Richard M, et al.
Publicado: (2015)

Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease
por: Gan, Liangying, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers
por: Tanaka, Jun, et al.
Publicado: (2012)

Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers*
por: Zecca, Ernesto, et al.
Publicado: (2015)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
por: Chait, Yossi, et al.
Publicado: (2022)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas
por: Zhai, John, et al.
Publicado: (2017)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric‐Onset Hypophosphatasia
por: Pan, Wei‐Jian, et al.
Publicado: (2021)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non‐obese volunteers
por: Chairat, Kalayanee, et al.
Publicado: (2016)

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
por: Jonsson, E. Niclas, et al.
Publicado: (2016)

Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?
por: Germovsek, Eva, et al.
Publicado: (2016)

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy
por: Xu, Xiaoying, et al.
Publicado: (2016)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation
por: Kloprogge, Frank, et al.
Publicado: (2015)

ADAM, a hands‐on patient simulator for teaching principles of drug disposition and compartmental pharmacokinetics
por: Zuna, Ines, et al.
Publicado: (2017)

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
por: Størset, Elisabet, et al.
Publicado: (2014)

Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians
por: Hasunuma, Tomoko, et al.
Publicado: (2016)

Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent
por: Nguyen, Ashley, et al.
Publicado: (2021)

Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects
por: Kawaguchi, Nao, et al.
Publicado: (2022)

A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS‐986231 in Healthy Volunteers
por: Cowart, Douglas, et al.
Publicado: (2019)

Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting
por: Shannon, Richard J, et al.
Publicado: (2014)

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE‐3
por: Berger, Rolf M. F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8dstec7o014oqr2hi8l3mct5r3